{
    "organizations": [],
    "uuid": "aae6908939906ac463c2ec598af6f8134133ef6d",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/02/business-wire-innoviva-to-report-fourth-quarter-financial-results-on-february-8-at-500-p-m-edt.html",
    "ord_in_thread": 0,
    "title": "Innoviva to Report Fourth Quarter Financial Results on February 8 at 5:00 p.m. EDT",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at 5:00 p.m. EDT/2:00 p.m. PDT to discuss the financial results and provide a corporate update.\nTo participate in the live call, dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers, and enter Conference ID: 2397629. A live webcast of the call will be available by following this link: INVA Earnings Call Webcast or from the investor relations section of the company website at www.inva.com and will be archived for 30 days. A telephone replay of the call will be available through February 15, by dialing (404) 537-3406.\nAbout Innoviva\nInnoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for TRELEGY® ELLIPTA® and earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at www.inva.com .\nANORO®, RELVAR®, BREO® and ELLIPTA® and TRELEGY® ELLIPTA®, are trademarks of the GlaxoSmithKline group of companies.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180202005556/en/\nInnoviva, Inc.\nEric d'Esparbes\nSenior Vice President and Chief Financial Officer\n650-238-9640\ninvestor.relations@inva.com\nSource: Innoviva, Inc.",
    "published": "2018-02-03T00:05:00.000+02:00",
    "crawled": "2018-02-03T01:02:55.023+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "brisbane",
        "business",
        "wire",
        "innoviva",
        "nasdaq",
        "inva",
        "announced",
        "today",
        "report",
        "financial",
        "result",
        "fourth",
        "quarter",
        "year",
        "ended",
        "december",
        "market",
        "close",
        "february",
        "following",
        "earnings",
        "release",
        "innoviva",
        "management",
        "host",
        "webcast",
        "conference",
        "call",
        "pdt",
        "discus",
        "financial",
        "result",
        "provide",
        "corporate",
        "update",
        "participate",
        "live",
        "call",
        "dial",
        "international",
        "caller",
        "enter",
        "conference",
        "id",
        "live",
        "webcast",
        "call",
        "available",
        "following",
        "link",
        "inva",
        "earnings",
        "call",
        "webcast",
        "investor",
        "relation",
        "section",
        "company",
        "website",
        "archived",
        "day",
        "telephone",
        "replay",
        "call",
        "available",
        "february",
        "dialing",
        "innoviva",
        "innoviva",
        "focused",
        "bringing",
        "compelling",
        "new",
        "medicine",
        "patient",
        "area",
        "unmet",
        "need",
        "leveraging",
        "significant",
        "expertise",
        "development",
        "commercialization",
        "financial",
        "management",
        "innoviva",
        "portfolio",
        "anchored",
        "respiratory",
        "asset",
        "partnered",
        "glaxo",
        "group",
        "limited",
        "gsk",
        "including",
        "jointly",
        "developed",
        "innoviva",
        "gsk",
        "agreement",
        "gsk",
        "innoviva",
        "eligible",
        "receive",
        "associated",
        "royalty",
        "revenue",
        "addition",
        "innoviva",
        "retains",
        "percent",
        "economic",
        "interest",
        "future",
        "payment",
        "made",
        "gsk",
        "program",
        "partnered",
        "theravance",
        "biopharma",
        "information",
        "please",
        "visit",
        "innoviva",
        "website",
        "trademark",
        "glaxosmithkline",
        "group",
        "company",
        "view",
        "source",
        "version",
        "http",
        "innoviva",
        "eric",
        "senior",
        "vice",
        "president",
        "chief",
        "financial",
        "officer",
        "source",
        "innoviva",
        "inc"
    ]
}